Drug intelligence / Profile preview

KD-416

Development stage: Unknown
Lead developer: KM Biologics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

KD-416 is a recombinant adsorbed hepatitis B vaccine being developed by KM Biologics, a subsidiary of Meiji Holdings. It is designed for the prevention of infection caused by the hepatitis B virus (HBV). The vaccine is produced using recombinant DNA technology to express the hepatitis B surface antigen (HBsAg), which is then adsorbed onto an adjuvant, typically aluminum hydroxide, to enhance the immune response. KD-416 is intended to provide a robust prophylactic option against HBV and is currently in Phase 3 clinical development in Japan.

Other names: Recombinant adsorbed hepatitis B vaccineHepatitis B vaccine (recombinant)

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on KD-416.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD-416.

Explore the full profile